Tuesday, December 07, 2021 2:28:47 PM
COURT DENIED $MRNA APPEAL;
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
BUY;Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment 11-19-2021
https://seekingalpha.com/article/4470947-arbutus-biopharma-recent-acquisition-of-dicerna-makes-it-an-attractive-investment
*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology.
Benzinga
also
12-01-2021
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
GlobeNewswire Inc.
Alert
Share On Facebook
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
Recent ABUS News
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:38:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:31:16 PM
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:09:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/21/2023 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:39 PM
- Arbutus to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:18:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:16 PM
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:16:12 PM
- Arbutus Announces CEO, William Collier, to Retire December 31, 2023 • GlobeNewswire Inc. • 11/07/2023 12:15:00 PM
- Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 10/24/2023 11:30:00 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM